1609963-01-0

Basic information

• Product Name: N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine
• Synonyms: N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine
• CAS NO: 1609963-01-0
• Molecular Weight: 430.528
• Mol File: 1609963-01-0.mol

Chemical Properties

• CAS DataBase Reference: N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine(CAS DataBase Reference)
• NIST Chemistry Reference: N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine(1609963-01-0)
• EPA Substance Registry System: N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine(1609963-01-0)

Safety Data

• Hazardous Substances Data: 1609963-01-0(Hazardous Substances Data)

Upstream product

• 1279865-14-3 2-amino-4-bromo-6-fluoro-benzonitrile 
• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 
• 1609962-87-9 N'-(5-bromo-2-cyano-3-fluoro-phenyl)-N,N-dimethyl-formamidine 
• 1520-31-6 dimethylsulfoximine 
• 1609963-00-9 N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine 

Downstream Products

• 1609960-66-8 C₂₀H₂₁FN₄O₄S 
• 1609960-67-9 C₂₁H₂₁F₃N₄O₄S 
• 1609963-02-1 N'-[2-cyano-3-(difluoromethoxy)-5-[[dimethyl(oxo)-λ⁶-sulfanylidene]amino]phenyl]-N,N-dimethylformamidine 
• 1609962-99-3 N′-[2-cyano-5-[[dimethyl(oxo)-λ⁶-sulfanylidene]amino]-3-hydroxyphenyl]-N,N-dimethylformamidine 

Relevant articles and documents

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.